BUSINESS● LOWSep 3 · Sep 3, 2026, 12:57 PM
Alumis downgraded at Guggenheim after trial setback for SLE candidate
Seeking Alpha Tech · north america
Alumis, a company, was downgraded by Guggenheim following a trial setback for its candidate drug for Systemic Lupus Erythematosus (SLE).
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS18m agoThousands of American restaurants closing over rising costs, declining salesCBS NewsBUSINESS52m ago‘Ticking time bomb’: The world's pension funds face an ageing crisisCNBC